India's Cipla: 'Huge wave' of pandemic-driven interest in health and wellness

India's Cipla also sees 30% to 40% of its pandemic-related sales lasting through the next two to three quarters as infection cases fluctuate, says Umang Vohra, managing director and global CEO of the multinational pharmaceutical firm.